NASDAQ:KDNY

Chinook Therapeutics Competitors

$15.90
+0.66 (+4.33 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$15.26
Now: $15.90
$15.93
50-Day Range
$13.60
MA: $16.66
$19.11
52-Week Range
$10.50
Now: $15.90
$21.68
Volume112,826 shs
Average Volume120,219 shs
Market Capitalization$673.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.26

Competitors

Chinook Therapeutics (NASDAQ:KDNY) Vs. RCKT, CORT, FOLD, GBT, ITCI, and LGND

Should you be buying KDNY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Chinook Therapeutics, including Rocket Pharmaceuticals (RCKT), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Intra-Cellular Therapies (ITCI), and Ligand Pharmaceuticals (LGND).

Chinook Therapeutics (NASDAQ:KDNY) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Profitability

This table compares Chinook Therapeutics and Rocket Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chinook Therapeutics-215.80%-112.72%-21.36%
Rocket PharmaceuticalsN/A-35.81%-27.52%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Chinook Therapeutics and Rocket Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chinook Therapeutics00803.00
Rocket Pharmaceuticals011302.93

Chinook Therapeutics presently has a consensus target price of $30.3333, suggesting a potential upside of 90.78%. Rocket Pharmaceuticals has a consensus target price of $59.1818, suggesting a potential upside of 36.40%. Given Chinook Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Chinook Therapeutics is more favorable than Rocket Pharmaceuticals.

Risk & Volatility

Chinook Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Earnings & Valuation

This table compares Chinook Therapeutics and Rocket Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chinook Therapeutics$17.26 million39.04$-82,370,000.00($5.15)-3.09
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-27.46

Rocket Pharmaceuticals has lower revenue, but higher earnings than Chinook Therapeutics. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats Chinook Therapeutics on 6 of the 11 factors compared between the two stocks.

Chinook Therapeutics (NASDAQ:KDNY) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Chinook Therapeutics and Corcept Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chinook Therapeutics-215.80%-112.72%-21.36%
Corcept Therapeutics30.73%25.38%23.16%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Chinook Therapeutics and Corcept Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chinook Therapeutics00803.00
Corcept Therapeutics01102.50

Chinook Therapeutics presently has a consensus price target of $30.3333, suggesting a potential upside of 90.78%. Corcept Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 5.40%. Given Chinook Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Chinook Therapeutics is more favorable than Corcept Therapeutics.

Insider and Institutional Ownership

75.4% of Corcept Therapeutics shares are held by institutional investors. 5.9% of Chinook Therapeutics shares are held by insiders. Comparatively, 16.4% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Chinook Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Valuation & Earnings

This table compares Chinook Therapeutics and Corcept Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chinook Therapeutics$17.26 million39.04$-82,370,000.00($5.15)-3.09
Corcept Therapeutics$306.49 million8.72$94.18 million$0.7729.57

Corcept Therapeutics has higher revenue and earnings than Chinook Therapeutics. Chinook Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Corcept Therapeutics beats Chinook Therapeutics on 10 of the 14 factors compared between the two stocks.

Chinook Therapeutics (NASDAQ:KDNY) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Chinook Therapeutics and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chinook Therapeutics-215.80%-112.72%-21.36%
Amicus Therapeutics-120.18%-73.81%-36.10%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Chinook Therapeutics and Amicus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chinook Therapeutics00803.00
Amicus Therapeutics07602.46

Chinook Therapeutics presently has a consensus price target of $30.3333, suggesting a potential upside of 90.78%. Amicus Therapeutics has a consensus price target of $20.0385, suggesting a potential upside of 101.59%. Given Amicus Therapeutics' higher probable upside, analysts clearly believe Amicus Therapeutics is more favorable than Chinook Therapeutics.

Risk and Volatility

Chinook Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Valuation & Earnings

This table compares Chinook Therapeutics and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chinook Therapeutics$17.26 million39.04$-82,370,000.00($5.15)-3.09
Amicus Therapeutics$182.24 million14.42$-356,390,000.00($1.31)-7.59

Chinook Therapeutics has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Chinook Therapeutics (NASDAQ:KDNY) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Chinook Therapeutics and Global Blood Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chinook Therapeutics-215.80%-112.72%-21.36%
Global Blood Therapeutics-332.94%-56.43%-39.32%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Chinook Therapeutics and Global Blood Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chinook Therapeutics00803.00
Global Blood Therapeutics051402.74

Chinook Therapeutics presently has a consensus price target of $30.3333, suggesting a potential upside of 90.78%. Global Blood Therapeutics has a consensus price target of $90.3158, suggesting a potential upside of 121.31%. Given Global Blood Therapeutics' higher probable upside, analysts clearly believe Global Blood Therapeutics is more favorable than Chinook Therapeutics.

Risk and Volatility

Chinook Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Valuation & Earnings

This table compares Chinook Therapeutics and Global Blood Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chinook Therapeutics$17.26 million39.04$-82,370,000.00($5.15)-3.09
Global Blood Therapeutics$2.11 million1,202.19$-266,770,000.00($4.71)-8.66

Chinook Therapeutics has higher revenue and earnings than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Chinook Therapeutics (NASDAQ:KDNY) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Chinook Therapeutics and Intra-Cellular Therapies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chinook Therapeutics00803.00
Intra-Cellular Therapies00703.00

Chinook Therapeutics presently has a consensus price target of $30.3333, suggesting a potential upside of 90.78%. Intra-Cellular Therapies has a consensus price target of $47.4286, suggesting a potential upside of 51.92%. Given Chinook Therapeutics' higher probable upside, research analysts clearly believe Chinook Therapeutics is more favorable than Intra-Cellular Therapies.

Valuation & Earnings

This table compares Chinook Therapeutics and Intra-Cellular Therapies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chinook Therapeutics$17.26 million39.04$-82,370,000.00($5.15)-3.09
Intra-Cellular Therapies$60,000.0042,103.81$-147,720,000.00($2.68)-11.65

Chinook Therapeutics has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Chinook Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Insider and Institutional Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. 5.9% of Chinook Therapeutics shares are held by insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Chinook Therapeutics and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chinook Therapeutics-215.80%-112.72%-21.36%
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%

Summary

Chinook Therapeutics beats Intra-Cellular Therapies on 7 of the 13 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Chinook Therapeutics (NASDAQ:KDNY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Ligand Pharmaceuticals and Chinook Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01602.86
Chinook Therapeutics00803.00

Ligand Pharmaceuticals currently has a consensus price target of $215.60, suggesting a potential upside of 43.51%. Chinook Therapeutics has a consensus price target of $30.3333, suggesting a potential upside of 90.78%. Given Chinook Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Chinook Therapeutics is more favorable than Ligand Pharmaceuticals.

Earnings & Valuation

This table compares Ligand Pharmaceuticals and Chinook Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million20.75$629.30 million$2.1171.20
Chinook Therapeutics$17.26 million39.04$-82,370,000.00($5.15)-3.09

Ligand Pharmaceuticals has higher revenue and earnings than Chinook Therapeutics. Chinook Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ligand Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Profitability

This table compares Ligand Pharmaceuticals and Chinook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Chinook Therapeutics-215.80%-112.72%-21.36%

Summary

Ligand Pharmaceuticals beats Chinook Therapeutics on 7 of the 12 factors compared between the two stocks.


Chinook Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39+0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77+0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94+3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81+1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22+3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26+5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73+0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57+2.6%$2.35 billion$33.94 million-88.91Gap Down
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13+5.6%$2.35 billion$15 million-17.35Unusual Options Activity
News Coverage
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22+0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96+1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68+0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15+0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77+1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44+1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02+0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22+3.5%$1.94 billion$410,000.00-5.92Analyst Report
Gap Down
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69+4.6%$1.91 billionN/A-25.40Increase in Short Interest
Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$31.83+2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73+3.2%$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59+3.1%$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91+3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08+0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70+0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89+0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61+2.2%$1.71 billion$428.41 million15.38News Coverage
Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70+0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06+1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87+0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29+1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15+0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30+2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35+2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07+4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95+4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52+2.4%$1.50 billion$82.27 million-18.34Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24+5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84+3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14+2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37+0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26+3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51+0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71+1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56+0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38+0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85+0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68+1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.